Home Newsfeeds Watching ContraFect; Hearing Zacks Small-Cap Research Sets $3 Valuation

Watching ContraFect; Hearing Zacks Small-Cap Research Sets $3 Valuation

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_09012022_CFRX_Bautz.pdf

byBenzinga Newsdesk

September 1, 2022

1 minute read

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_09012022_CFRX_Bautz.pdf

Walmart, Cisco And 3 Stocks To Watch Heading Into Thursday

By Lisa Levin

August 17, 4:34 AM

With U.S. stock futures trading mixed this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

AMAT

$1000 Invested In NVIDIA 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 29, 10:08 AM

NVIDIA (NASDAQ:NVDA) has outperformed the market over the past 5 years by 20.37% on an annualized basis producing an average annual return of 30.57%. Currently, NVIDIA has a market capitalization of $404.31 billion.

NVDA

HCA Healthcare Gets Price Target Bumps By Analysts After Upbeat Q1 Results

By Lisa Levin

April 24, 7:56 AM

HCA Healthcare (NYSE: HCA) reported better-than-expected Q1 results and revised FY23 guidance.

HCA

Bristol Myers’ Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study

By Vandana Singh

September 22, 10:18 AM

Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy followed by surgery and

BMY

Watching ContraFect; Hearing Zacks Small-Cap Research Sets $3 Valuation

Related Posts

Walmart, Cisco And 3 Stocks To Watch Heading Into Thursday

$1000 Invested In NVIDIA 5 Years Ago Would Be Worth This Much Today

HCA Healthcare Gets Price Target Bumps By Analysts After Upbeat Q1 Results

Bristol Myers’ Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study